Navin Pinto
YOU?
Author Swipe
View article: Supplementary fig 3 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Supplementary fig 3 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report Open
Supplemental Figure S3 Non-negative Matrix Factorization (NMF) Clustering of Tumor Specimens. (A) Clustering similarity matrix and (B) Silhouette plot of samples by cluster id. (C) Enrichment score for adrenergic (ADRN), mesenchymal (MES),…
View article: Supplementary Figure S1 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Supplementary Figure S1 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report Open
Supplemental Figure S1 Outcome by Chromosome 5 Status. (A) EFS and (B) OS by Chromosome 5 status
View article: Supplementary fig 2 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Supplementary fig 2 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report Open
Supplemental Figure S2 Outcome by Chromosome 9 Status. (A) EFS and (B) OS by Chromosome 9 status
View article: UCD19 CAR-T cell therapy for adults with B-cell acute lymphoblastic leukemia in first complete remission with MRD positivity: Preliminary Results of A phase I/ib clincal trial
UCD19 CAR-T cell therapy for adults with B-cell acute lymphoblastic leukemia in first complete remission with MRD positivity: Preliminary Results of A phase I/ib clincal trial Open
Introduction For adults with newly diagnosed B-ALL who achieve complete remission after induction therapy, detectable minimal residual disease (MRD) at end of induction is a significant risk factor for relapse. CD19 CAR-T cell therapy resu…
View article: Efficacy, safety, and pharmacokinetics of eribulin as monotherapy or in combination with irinotecan for patients with pediatric rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, or Ewing sarcoma
Efficacy, safety, and pharmacokinetics of eribulin as monotherapy or in combination with irinotecan for patients with pediatric rhabdomyosarcoma, non-rhabdomyosarcoma soft tissue sarcoma, or Ewing sarcoma Open
View article: Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial
Intracerebroventricular B7-H3-targeting CAR T cells for diffuse intrinsic pontine glioma: a phase 1 trial Open
View article: Intracerebroventricular B7-H3 CAR T cells for children and young adults with diffuse intrinsic pontine glioma
Intracerebroventricular B7-H3 CAR T cells for children and young adults with diffuse intrinsic pontine glioma Open
Diffuse intrinsic pontine glioma (DIPG) is a fatal central nervous system (CNS) tumor with a median survival of 11 months. Chimeric antigen receptor (CAR) T cells are clinically effective against hematologic malignancies, but there are lim…
View article: 233 Early experience on ENLIGHTen-01: a phase 1 study of FITC-E2 CAR-T cells with CAR adaptor molecule UB-TT170 for relapsed/refractory osteosarcoma
233 Early experience on ENLIGHTen-01: a phase 1 study of FITC-E2 CAR-T cells with CAR adaptor molecule UB-TT170 for relapsed/refractory osteosarcoma Open
View article: Response to induction chemotherapy modifies the effect of conventional prognostic factors in high-risk neuroblastoma: A report from the Children’s Oncology Group
Response to induction chemotherapy modifies the effect of conventional prognostic factors in high-risk neuroblastoma: A report from the Children’s Oncology Group Open
The impact of conventional prognostic factors is not static in patients with HR-NB. Instead, response to induction chemotherapy modifies the effect of conventional prognostic factors. These data can help to further refine prognosis for pat…
View article: Locoregional CAR T Cells for the Treatment of CNS Tumors in Children: Investigational Drug Service Pharmacy Activities.
Locoregional CAR T Cells for the Treatment of CNS Tumors in Children: Investigational Drug Service Pharmacy Activities. Open
As the field of adoptive immunotherapy grows and continues to bring hope to patients with fatal CNS malignancies, it is critical to focus on improving the preparatory steps for CAR T-cell delivery.
View article: First-in-human comparison of second- versus third-generation L1CAM-specific CAR T cells in patients with primary refractory or relapsed neuroblastoma
First-in-human comparison of second- versus third-generation L1CAM-specific CAR T cells in patients with primary refractory or relapsed neuroblastoma Open
Outcomes for children with relapsed and refractory neuroblastoma are dismal. ENCIT-01 is our first-in-human experience in patients with relapsed and refractory neuroblastoma using chimeric antigen receptor (CAR) T cells targeting L1-CAM, a…
View article: TRLS-12. INTRAVENTRICULAR B7-H3 CAR T CELLS FOR DIFFUSE INTRINSIC PONTINE GLIOMA: INTERIM ANALYSIS OF BRAINCHILD-03 ARM C
TRLS-12. INTRAVENTRICULAR B7-H3 CAR T CELLS FOR DIFFUSE INTRINSIC PONTINE GLIOMA: INTERIM ANALYSIS OF BRAINCHILD-03 ARM C Open
BACKGROUND BrainChild-03 is a first-in-human phase 1 clinical trial delivering repeated intraventricular B7-H3 CAR T cells to children with central nervous system (CNS) tumors without lymphodepleting chemotherapy. METHODS We report on the …
View article: Supplementary fig 2 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Supplementary fig 2 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report Open
Supplemental Figure S2 Outcome by Chromosome 9 Status. (A) EFS and (B) OS by Chromosome 9 status
View article: Supplementary Figure S1 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Supplementary Figure S1 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report Open
Supplemental Figure S1 Outcome by Chromosome 5 Status. (A) EFS and (B) OS by Chromosome 5 status
View article: Supplementary Figure S1 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Supplementary Figure S1 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report Open
Supplemental Figure S1 Outcome by Chromosome 5 Status. (A) EFS and (B) OS by Chromosome 5 status
View article: Data from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Data from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report Open
Purpose:Patients ≥18 months of age with International Neuroblastoma Staging System (INSS) stage 3 unfavorable histology (UH), MYCN-nonamplified (MYCN-NA) tumors have favorable survival rates compared with other high-risk neur…
View article: Supplementary fig 3 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Supplementary fig 3 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report Open
Supplemental Figure S3 Non-negative Matrix Factorization (NMF) Clustering of Tumor Specimens. (A) Clustering similarity matrix and (B) Silhouette plot of samples by cluster id. (C) Enrichment score for adrenergic (ADRN), mesenchymal (MES),…
View article: Supplementary fig 2 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Supplementary fig 2 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report Open
Supplemental Figure S2 Outcome by Chromosome 9 Status. (A) EFS and (B) OS by Chromosome 9 status
View article: Supplementary fig 3 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Supplementary fig 3 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report Open
Supplemental Figure S3 Non-negative Matrix Factorization (NMF) Clustering of Tumor Specimens. (A) Clustering similarity matrix and (B) Silhouette plot of samples by cluster id. (C) Enrichment score for adrenergic (ADRN), mesenchymal (MES),…
View article: Data from Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety
Data from Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety Open
Diffuse intrinsic pontine glioma (DIPG) remains a fatal brainstem tumor demanding innovative therapies. As B7-H3 (CD276) is expressed on central nervous system (CNS) tumors, we designed B7-H3–specific chimeric antigen receptor (CAR) T cell…
View article: Supplementary Data from Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety
Supplementary Data from Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety Open
Supplementary Data from Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety
View article: Supplementary Data from Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety
Supplementary Data from Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety Open
Supplementary Data from Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety
View article: Data from Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety
Data from Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety Open
Diffuse intrinsic pontine glioma (DIPG) remains a fatal brainstem tumor demanding innovative therapies. As B7-H3 (CD276) is expressed on central nervous system (CNS) tumors, we designed B7-H3–specific chimeric antigen receptor (CAR) T cell…
View article: Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results Open
Neuroblastomas harbor ALK aberrations clinically resistant to crizotinib yet sensitive pre-clinically to the third-generation ALK inhibitor lorlatinib. We conducted a first-in-child study evaluating lorlatinib with and without chemotherapy…
View article: Supplementary fig 2 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Supplementary fig 2 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report Open
Supplemental Figure S2 Outcome by Chromosome 9 Status. (A) EFS and (B) OS by Chromosome 9 status
View article: Supplementary fig 3 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Supplementary fig 3 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report Open
Supplemental Figure S3 Non-negative Matrix Factorization (NMF) Clustering of Tumor Specimens. (A) Clustering similarity matrix and (B) Silhouette plot of samples by cluster id. (C) Enrichment score for adrenergic (ADRN), mesenchymal (MES),…
View article: Data from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Data from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report Open
Purpose:Patients ≥18 months of age with International Neuroblastoma Staging System (INSS) stage 3 unfavorable histology (UH), MYCN-nonamplified (MYCN-NA) tumors have favorable survival rates compared with other high-risk neur…
View article: Supplementary fig 2 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Supplementary fig 2 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report Open
Supplemental Figure S2 Outcome by Chromosome 9 Status. (A) EFS and (B) OS by Chromosome 9 status
View article: Supplementary Figure S1 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Supplementary Figure S1 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report Open
Supplemental Figure S1 Outcome by Chromosome 5 Status. (A) EFS and (B) OS by Chromosome 5 status
View article: Supplementary Figure S1 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report
Supplementary Figure S1 from Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without <i>MYCN</i> Amplification: A Children's Oncology Group (COG) Report Open
Supplemental Figure S1 Outcome by Chromosome 5 Status. (A) EFS and (B) OS by Chromosome 5 status